48results about "Antibodies" patented technology

Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.

The invention discloses a method for preparing L-phosphinothricin through de-racemization by a biological enzyme method, a phosphinothricin dehydrogenase mutant and an application. According to the method for preparing L-phosphinothricin through de-racemization by a biological enzyme method, D,L-phosphinothricin is used as a raw material, through catalysis with a multienzyme catalysis system, theL-phosphinothricin is obtained, wherein the enzyme catalysis system comprises D-amino acid oxidase which is used for catalyzing D-phosphinothricin in the D,L-phosphinothricin into 4-(hydroxymethylphosphinyl)-2-oxobutanoic, and the phosphinothricin dehydrogenase mutant which is used for performing catalytic reduction on the 4-(hydroxymethylphosphinyl)-2-oxobutanoic to obtain the L-phosphinothricin,the phosphinothricin dehydrogenase mutant is obtained through mutation of phosphinothricin dehydrogenase in wild mushrooms Thiopseudomonas denitrificans, and a mutation site is V377S. The phosphinothricin dehydrogenase mutant disclosed by the invention has better catalysis efficiency, when a catalytic reaction is performed by using racemation D,L-phosphinothricin as a substrate, the conversion rate is far higher than that of a catalytic reaction performed by using a wild type enzyme as a substrate, and the PPO yield is also substantially increased.

The present invention relates to expression and assembly of foreign multimeric proteins—e.g., antibodies—in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional secretory antibodies in plants is disclosed. The invention also discloses compositions produced by the transgenic plants of the present invention and methods of using same.

There are provided an anti-nucleic acid antibody inducing cell death of cancer cells by invading normal cells; and a composition for preventing or treating cancers comprising the anti-nucleic acid antibody, which shows anticancer effect of an anti-nucleic acid antibody that shows cytotoxicity by damaging nucleic acid strands, that is, genetic information of a cancer cell when the anti-nucleic acid antibody, which has binding activity and degrading activity to the nucleic acid strands in cells at the same time, is overexpressed in the cancer cell, or flows in the cancer cell. Therefore, the composition for treating cancers may be useful to induce the selective cell death in cancer cells than in normal cells since the anti-nucleic acid antibody very easily permeates into the cancer cells due to the excellent selectivity, compared to the normal cells.